- Global Pharma News & Resources

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2021:Scope,Covid-19 Impact Analysis ,Business Growth Factors, Industry Policies And Forecast To 2027||Merck & Co., Inc., Myriad Genetics, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc

Data Bridge Market research released a new market study on  Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In   Poly (ADP-Ribose) Polymerase (PARP) Inhibitors research report also directs the manufacturer about planning of advertising and sales promotion efforts and makes it more effective. The report consists of all the detailed profiles for the  Poly (ADP-Ribose) Polymerase (PARP) Inhibitors major manufacturers and importers who are influencing the market.  Poly (ADP-Ribose) Polymerase (PARP) Inhibitors survey provides key information about the industry such as helpful and important facts and figures, expert opinions, and the latest developments across the globe. This market study includes drivers and restraints for the market along with the impact they have on the demand over the forecast period derived with the help of SWOT analysis.

Global poly (ADP-ribose) polymerase (PARP) inhibitors market is rising gradually with a healthy CAGR of 24.7% in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. Increasing approvals of novel PARP inhibitors and mergers & acquisitions of many pharmaceutical companies brings a great opportunity for growth of the market.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @

Few of the major competitors currently working in the global poly (ADP-ribose) polymerase (PARP) inhibitors market are

  • Pfizer Inc.,
  • CLOVIS ONCOLOGY, AstraZeneca,
  • Merck & Co., Inc., Myriad Genetics, Inc.,
  • GlaxoSmithKline plc., Johnson & Johnson Services, Inc.,
  • AbbVie Inc., Myriad Genetics, Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • Checkpoint Therapeutics, Inc.,
  • Takeda Pharmaceutical Company Limited,
  • Artios Pharma, Genentech, Inc.,
  • onxeo, Bristol-Myers Squibb Company,
  • Sierra Oncology, Inc.,
  • Karyopharm Therapeutics,
  • Repare Therapeutics among others.

Key Developments in the Market:

In October 2018, Pfizer Inc. received the U.S FDA approval for Talzenna (talazoparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for treatment of patients with breast cancer. The drug candidate shows potential effectiveness in deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. The novel drug candidate will provide an effective treatment to the patients suffering from breast cancer and Pfizer Inc. will expand its business revenue by production and commercialization of the drug

In April 2018, CLOVIS ONCOLOGY received the U. S. FDA approval for Rubraca, a poly ADP-ribose polymerase (PARP) inhibitor used for treatment of patients with recurrent epithelial ovarian cancer. The novel drug candidate will provide an effective treatment to the patients suffering from recurrent epithelial ovarian cancer enabling the company in expanding its business revenue

What Managed Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research Offers:

  • Managed poly (ADP-ribose) polymerase (PARP) inhibitors Industry gives assessments for the regional level analysis with Production, Sales, Consumption, Imports and Exports
  • Managed poly (ADP-ribose) polymerase (PARP) inhibitors industry provides manufacturers with basic information, product category, sales revenue, price, and gross margin (2020-2027)
  • Managed poly (ADP-ribose) polymerase (PARP) inhibitors market forecasts for a minimum of 7 years of all the mentioned segments
  • Supply chain trends mapping the latest technological advancements
  • Global Managed poly (ADP-ribose) polymerase (PARP) inhibitors industry shares drivers, constraints, opportunities, threats, challenges, investment opportunities
  • Strategic for the new entrants in Managed poly (ADP-ribose) polymerase (PARP) inhibitors market
  • Manufacturing process, suppliers, price, production and consumption analysis, mode of transport and cost analysis, industry chain analysis
  • Company profiling with detailed strategies, financials, and recent developments

Enquire Here for, Report Enquiry, Discount and Customization:

Segmentation: Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market By Drugs Type

  • Talazoparib
  • Veliparib
  • Olaparib
  • Others

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market By Indication Type

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Breast Cancer
  • Others

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market By Distribution Channels

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Get Full Report @

Market Drivers

  • Rising incidence rate of cancer demanding novel therapies increases the anticipation of PARP inhibitors driving the market growth
  • Rising awareness about PARP inhibitors for treatment of cancer will expand the market size
  • Increasing geriatric population and prevailing cancer disease will also boost the growth of the market
  • Governmental investment in improvement of health expenditure is another factor fueling this market growth

Market Restraints

  • Side effects of PARP inhibitors hampers the market growth
  • Resistance of PARP inhibitors is another factor restraining the growth of the market Stringent regulatory policies will also restrict the market growth

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Landscape

  • Market Ecosystem
  • Market Characteristics
  • Market Segmentation Analysis

Part 05: Market Sizing

  • Market Definition
  • Market Sizing 2020
  • Market Size And Forecast 2020-2027

Part 06: Customer Landscape

Part 07: Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional Landscape

  • Geographical Segmentation
  • Regional Comparison
  • Americas – Market Size And Forecast 2020-2027
  • EMEA – Market Size And Forecast 2020-2027
  • APAC – Market Size And Forecast 2020-2027

Part 08: Decision Framework

Part 09: Drivers And Challenges

  • Market Drivers
  • Market Challenges

Part 10: Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends

Part 11: Vendor Landscape

  • Overview
  • Landscape Disruption
  • Vendors Covered
  • Vendor Classification
  • Market Positioning Of Vendors

To receive extensive list of important regions, ask for TOC here

Focal Points Covered In This Statistical Survey Report 

  • This Poly (ADP-Ribose) Polymerase (PARP) Inhibitors report provides pin point analysis of the market outlook and later establishes its comparison with current patterns. Also it creates a relationship of the market outlook with Porter Five Force Analysis
  • This research report is inclusive concept of the market progression. The market progression considers the components of the present situation and compares the current scenario of the market with future developmental chances.
  • The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors research report includes investigation at global and regional levels. These comprehensive and local level investigations are inclusive of the request as well as the supply powers which in turn willingly or unwillingly affects the market development
  • Various Topics such as product offering, finance related data, recent developments, analysis of Strengths, weakness, Opportunities and Threats in the upcoming scenario are highlighted in this research report.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing . We are content with our glorious 99.9 % client satisfying rate.


Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475


This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 15-Jan-2021